Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Tebentafusp in Patients With Locally Advanced, Unresectable Primary Uveal Melanoma

NCT06414590 is registered in ClinicalTrials.gov with Thomas Jefferson University as lead sponsor.

NCT NCT06414590
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06414590 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Tebentafusp in Patients With Locally Advanced, Unresectable Primary Uveal Melanoma
Lead sponsor
Thomas Jefferson University
Phase
Phase 2
Overall status
Recruiting
Start date
September 5, 2025
Completion date
March 31, 2032
Enrollment
19 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced unresectable uveal melanoma